Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study

Autor: Yun Fan, Jin Qin, Fajun Xie, Lei Gong, Xiaoling Xu, Wenfeng Li, Xun Shi, Yuping Li, Weizhen Xu, Jun Chen, Zhiyu Huang, Ying Jin, Na Han, Yanjun Xu, Hongyang Lu, Ming Chen, Kaiyan Chen, Peng Zhang, Jun Zhao, Xin-ming Yu
Rok vydání: 2019
Předmět:
Adult
Male
Oncology
Cancer Research
medicine.medical_specialty
Lung Neoplasms
Pyridines
Population
Antineoplastic Agents
Platinum Compounds
Article
Small-cell lung cancer
03 medical and health sciences
chemistry.chemical_compound
Targeted therapies
0302 clinical medicine
Internal medicine
medicine
Clinical endpoint
Humans
Apatinib
Treatment Failure
Progression-free survival
education
Prospective cohort study
Lung cancer
Survival rate
Aged
030304 developmental biology
0303 health sciences
education.field_of_study
Brain Neoplasms
business.industry
Liver Neoplasms
gamma-Glutamyltransferase
Middle Aged
medicine.disease
Small Cell Lung Carcinoma
Progression-Free Survival
Survival Rate
Regimen
Treatment Outcome
chemistry
030220 oncology & carcinogenesis
Hypertension
Female
Hand-Foot Syndrome
business
Zdroj: British Journal of Cancer
ISSN: 1532-1827
0007-0920
DOI: 10.1038/s41416-019-0583-6
Popis: BackgroundSmall-cell lung cancer (SCLC) remains an aggressive cancer with short-term survival due to limited therapeutic options. Apatinib is a small-molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor-2. This study aimed to investigate the efficacy and safety of apatinib in patients with extensive-stage (EC) SCLC who had progressed after two or three previous therapies.MethodsEligible patients were histologically confirmed ES-SCLC after two or three previous treatments, including a platinum-based regimen. Patients received apatinib at an initial dose of 500 mg once daily. The primary endpoint was the objective response rate.ResultsForty patients were enrolled. At the data cut-off time (November 15, 2018), the median follow-up was 7.4 months; no patients remained on treatment, and five were still in follow-up. An objective response was achieved in 7 of 40 patients (17.5%) in the intention-to-treat population, and 7 of 38 patients (18.4%) in the per-protocol population. The median progression-free survival and overall survival were 3.0 months and 5·8 months, respectively. The most commonly observed grade 3 or greater treatment-related adverse events were hypertension, hand–foot syndrome, increased L-gamma-glutamyltransferase.ConclusionsApatinib exhibited efficacy and an acceptable safety profile in previously heavily-treated ES-SCLC patients. Further exploration of apatinib in phase III trials is warranted.Trial registrationNCT02945852.
Databáze: OpenAIRE
Externí odkaz: